title: Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia.
abstract: The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.
authors.affiliation: Department of Hematology; Cancer Center Amsterdam; VU Institute for Cancer and Immunology; VU University Medical Center ; Amsterdam, The Netherlands ; Department of Immunology; Erasmus MC University Medical Center ; Rotterdam, The Netherlands.
authors.forename: Marvin M
authors.initials: MM
authors.lastname: van Luijn
authors.affiliation: Department of Hematology; Cancer Center Amsterdam; VU Institute for Cancer and Immunology; VU University Medical Center ; Amsterdam, The Netherlands.
authors.forename: Willemijn
authors.initials: W
authors.lastname: van den Ancker
authors.affiliation: Department of Immunopathology; Sanquin Research and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam ; Amsterdam, The Netherlands.
authors.forename: S Marieke
authors.initials: SM
authors.lastname: van Ham
authors.affiliation: Department of Hematology; Cancer Center Amsterdam; VU Institute for Cancer and Immunology; VU University Medical Center ; Amsterdam, The Netherlands.
authors.forename: Arjan A
authors.initials: AA
authors.lastname: van de Loosdrecht
keywords: CD4+ T cells; HLA; immune escape; leukemia-associated phenotype; minimal residual disease